Kevin Dale Courtney, M.D., Ph.D., is an Associate Professor in the Department of Internal Medicine at UT Southwestern Medical Center and a member of the Division of Hematology and Oncology.

A native of New Hampshire, Dr. Courtney earned his medical degree and a doctorate in molecular cancer biology at Duke University in North Carolina. He completed internal medicine residency training at the University of California-San Francisco, and then received advanced training through a clinical fellowship in medical oncology at the Dana-Farber Cancer Institute/Dana-Farber Harvard Cancer Center and a postdoctoral research fellowship at Beth Israel Deaconess Medical Center, both in Boston. He also holds a master’s degree in clinical sciences from UT Southwestern.

Certified by the American Board of Internal Medicine in medical oncology, Dr. Courtney joined the UT Southwestern faculty in 2012.

Dr. Courtney’s clinical and translational research efforts focus on prostate and kidney cancer and other genitourinary cancers. His investigations have led to more than 40 publications in peer-reviewed journals, reviews, and editorials.

Dr. Courtney is a member of the American Society of Clinical Oncology. He also serves as a medical advisor to the North Texas Prostate Cancer Coalition, a volunteer organization of prostate cancer survivors and family members.


Other Post Graduate Training
Duke University School of Medicine (2001)
Graduate School
Duke University School of Medicine (2001)
Medical School
Duke University School of Medicine (2002)
University of California, San Francisco (2005), Internal Medicine
Dana-Farber Cancer Institute (2008), Oncology

Research Interest

  • Clinical-translational research in genitourinary oncology
  • Industry- and cooperative group-sponsored trials in genitourinary malignancies
  • Investigator-initiated clinical trials in kidney cancer
  • Investigator-initiated clinical trials in prostate cancer
  • Novel biomarkers and therapeutics in prostate and kidney cancer


Featured Publications LegendFeatured Publications

HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma.
Courtney KD*, Ma Y*, Diaz de Leon A*, Christie A, Xie Z, Woolford L, Singla N, Joyce A, Hill H, Madhuranthakam AJ, Yuan Q, Xi Y, Zhang Y, Chang J, Fatunde O, Arriaga Y, Frankel AE, Kalva S, Zhang S, McKenzie T, Reig Torras O, Figlin RA, Rini BI, McKay RM, Kapur P, Wang T, Pedrosa I, Brugarolas J. Clin Cancer Res. 2019
Salvage Radiotherapy for Nodal Oligorecurrent Prostate Cancer: A Step Towards Predictive Criteria for Metastasis-Directed Therapy in Prostate Cancer?
Desai NB, Courtney K, Subramaniam RM, Cadeddu JA. Eur Urol. 2019 76 740-742
MCT2 mediates concentration-dependent inhibition of glutamine metabolism by MOG.
Fets L, Driscoll PC, Grimm F, Jain A, Nunes PM, Gounis M, Doglioni G, Papageorgiou G, Ragan TJ, Campos S, Silva Dos Santos M, MacRae JI, O'Reilly N, Wright AJ, Benes CH, Courtney KD, House D, Anastasiou D Nat. Chem. Biol. 2018 Nov 14 11 1032-1042


Featured Books Legend Featured Books

Honors & Awards

  • John W. Boddie, Ph.D. & Joan Reisch, Ph.D. Fund in Prostate Cancer Research in Honor of Dr. Kevin Courtney
  • Wheels for Wellness Classic Hero Award of Gratitude from the Wheels for Wellness Foundation and Moncrief Cancer Institute
  • UT Southwestern Golden Pager Award
  • Career Development Award
    Genentech, Inc. Dana-Farber/Partners Cancer Center (2008)
  • Young Investigator Award
    American Society of Clinical Oncology (2008)
  • Sigma Xi
    Member (1993)
  • Phi Beta Kappa
    Membership (1992)

Professional Associations/Affiliations

  • American Society of Clinical Oncology (2008)